Search results
Earnings call: Vaxart posts progress in vaccine trials, Q1 financials By Investing.com
Investing.com· 1 hour agoVaxart, Inc. (NASDAQ: NASDAQ:VXRT), a biotechnology company specializing in the development of oral...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer...
WKBN 27 Youngstown· 53 minutes agoGLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended ...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
NBC 10 - FOX 14 Monroe· 4 hours ago"We are pleased that the feedback from the U.S. Food and Drug Administration (FDA) supports the advancement of larsucosterol into a single pivotal Phase ...
Cardurion’s PDE9 inhibitor increases cGMP in Phase IIa heart failure trial
Clinical Trials Arena via Yahoo Finance· 15 hours agoCardurion Pharmaceuticals has said its phosphodiesterase-9 (PDE9) inhibitor, CRD-740, has met the...
Clinical trial investigating aficamten meets primary endpoint in obstructive hypertrophic...
Medical Xpress· 5 hours agoEven though mortality and hospitalization rates have improved, the quality of life for those living...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 4 hours agoMass Eye and Ear researchers say their findings support continued research and clinical trials of...
Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel...
WRBL Columbus· 3 days ago"At ASGCT, Replicate is presenting two important breakthroughs in srRNA...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 8 hours agoMerck announced Monday that it is pulling the plug on its phase 3 trial of an experimental...
As the FDA evaluates ecstasy treatment for PTSD, questions mount about the evidence
KPBS San Diego· 12 hours agoAn approval by the agency would represent an enormous milestone for the movement to bring psychedelics into the mainstream of mental health care. An FDA rejection
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 12 hours agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...